CN101534853A - 胸腺素α-1用于制备预防及治疗自身免疫性疾病的药物 - Google Patents

胸腺素α-1用于制备预防及治疗自身免疫性疾病的药物 Download PDF

Info

Publication number
CN101534853A
CN101534853A CNA200780040140XA CN200780040140A CN101534853A CN 101534853 A CN101534853 A CN 101534853A CN A200780040140X A CNA200780040140X A CN A200780040140XA CN 200780040140 A CN200780040140 A CN 200780040140A CN 101534853 A CN101534853 A CN 101534853A
Authority
CN
China
Prior art keywords
disease
thymosin
ibd
thymosin alpha
colitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780040140XA
Other languages
English (en)
Chinese (zh)
Inventor
L·罗马尼
F·比斯托尼
E·加拉西
G·拉斯
P·西尼巴迪瓦莱波纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101534853A publication Critical patent/CN101534853A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA200780040140XA 2006-10-27 2007-09-27 胸腺素α-1用于制备预防及治疗自身免疫性疾病的药物 Pending CN101534853A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2006A000584 2006-10-27
IT000584A ITRM20060584A1 (it) 2006-10-27 2006-10-27 Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni

Publications (1)

Publication Number Publication Date
CN101534853A true CN101534853A (zh) 2009-09-16

Family

ID=39322489

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780040140XA Pending CN101534853A (zh) 2006-10-27 2007-09-27 胸腺素α-1用于制备预防及治疗自身免疫性疾病的药物

Country Status (13)

Country Link
US (1) US20100004174A1 (enExample)
EP (1) EP2086569A2 (enExample)
JP (1) JP2010507650A (enExample)
KR (1) KR20090096688A (enExample)
CN (1) CN101534853A (enExample)
AU (1) AU2007310416A1 (enExample)
BR (1) BRPI0718010A2 (enExample)
CA (1) CA2666609A1 (enExample)
EA (1) EA200900602A1 (enExample)
IL (1) IL198291A0 (enExample)
IT (1) ITRM20060584A1 (enExample)
MX (1) MX2009004196A (enExample)
WO (1) WO2008050363A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100248272A1 (en) * 2009-03-31 2010-09-30 Cornell University Method for identifying Smk box riboswitch modulating compounds
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW249754B (enExample) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
CA2270223A1 (en) * 1996-10-28 1998-05-07 Carson B. Burgstiner (Deceased) Methods and compositions for dietary supplementation
CN1198950A (zh) * 1998-04-24 1998-11-18 崔泊 一种结肠炎新药的制备
CN1628796A (zh) * 2004-08-20 2005-06-22 康合堂 一种治疗溃疡性结肠炎的药物

Also Published As

Publication number Publication date
WO2008050363A8 (en) 2009-06-04
WO2008050363A2 (en) 2008-05-02
MX2009004196A (es) 2009-06-30
WO2008050363A3 (en) 2008-06-26
CA2666609A1 (en) 2008-05-02
JP2010507650A (ja) 2010-03-11
EA200900602A1 (ru) 2009-10-30
IL198291A0 (en) 2011-08-01
BRPI0718010A2 (pt) 2013-11-19
EP2086569A2 (en) 2009-08-12
US20100004174A1 (en) 2010-01-07
KR20090096688A (ko) 2009-09-14
AU2007310416A1 (en) 2008-05-02
ITRM20060584A1 (it) 2008-04-28

Similar Documents

Publication Publication Date Title
Shichita et al. Neuroimmune mechanisms and therapies mediating post-ischaemic brain injury and repair
Scherrer et al. Behcet's disease: review with emphasis on dermatological aspects
Zong et al. The role of il‐17 promotes spinal cord neuroinflammation via activation of the transcription factor stat3 after spinal cord injury in the rat
CA2513567C (en) Cop 1 for treatment of inflammatory bowel diseases
US8771689B2 (en) Alpha B-crystallin as a therapy for ischemia or inflammation
WO2003083067A2 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
Ahmed et al. A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis
KR101951787B1 (ko) mTOR 저해제를 함유하는 황반변성 치료용 의약조성물
Lehmann et al. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis
Déchelle-Marquet et al. P2X7-dependent immune pathways in retinal diseases
Ghorbani et al. Melittin administration ameliorates motor function, prevents apoptotic cell death and protects Purkinje neurons in the rat model of cerebellar ataxia induced by 3-Acetylpyridine
Jin et al. The protective effects of nesfatin‐1 in neurological dysfunction after spinal cord injury by inhibiting neuroinflammation
JP2010512403A (ja) 炎症の治療法としてのαＢクリスタリン
BRPI0923832B1 (pt) Uso de um peptídeo tipo apl para o tratamento de doenças inflamatórias intestinais e diabetes tipo 1.
CN101534853A (zh) 胸腺素α-1用于制备预防及治疗自身免疫性疾病的药物
CN1070868C (zh) 用作自身免疫性疾病治疗剂的肽
Zhu et al. Ganoderma lucidum polysaccharide attenuates retinal ischemia-reperfusion injury by regulating microglial M1/M2 polarization, suppressing neuroinflammation and inhibiting JAK2/STAT3 pathway
Shen et al. Phosphatase and tensin homolog deleted on chromosome ten knockdown attenuates cognitive deficits by inhibiting neuroinflammation in a mouse model of perioperative neurocognitive disorder
Charles et al. Past and Present Beh's Disease Animal Models
Dachs et al. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy
CN108210886A (zh) Metrnl在防治溃疡性结肠炎中的应用
HK1137651A (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
Jiang et al. cGAS-STING signaling regulates control of microglia polarization in cerebral ischemic stroke
Balch et al. Appropriate Timing of Fluoxetine and Statin Delivery Reduces the Risk of Secondary Bleeding in Ischemic Stroke Rats
Damerau et al. AB0331 DEVELOPMENT OF AN ANIMAL-FREE 3D IN VITRO SYNOVIAL MEMBRANE MODEL FOR PRECISE STUDY OF ARTHRITIC PROCESSES

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1137651

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090916

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1137651

Country of ref document: HK